Bluejay Diagnostics (Bluejay Diagnostics) Long-Term Capital Lease Obligation : $0.17 Mil (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Bluejay Diagnostics Long-Term Capital Lease Obligation?

Bluejay Diagnostics's Long-Term Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.17 Mil.

Bluejay Diagnostics's quarterly Long-Term Capital Lease Obligation declined from Sep. 2023 ($0.22 Mil) to Dec. 2023 ($0.19 Mil) and declined from Dec. 2023 ($0.19 Mil) to Mar. 2024 ($0.17 Mil).

Bluejay Diagnostics's annual Long-Term Capital Lease Obligation increased from Dec. 2021 ($0.00 Mil) to Dec. 2022 ($0.32 Mil) but then declined from Dec. 2022 ($0.32 Mil) to Dec. 2023 ($0.19 Mil).

Bluejay Diagnostics Long-Term Capital Lease Obligation Historical Data

The historical data trend for Bluejay Diagnostics's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bluejay Diagnostics Long-Term Capital Lease Obligation Chart

Bluejay Diagnostics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Capital Lease Obligation

0.32

0.19

Bluejay Diagnostics Quarterly Data
	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial												0.29	0.26	0.22	0.19	0.17

Bluejay Diagnostics (NAS:BJDX) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Bluejay Diagnostics Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Bluejay Diagnostics's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Bluejay Diagnostics (Bluejay Diagnostics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Bluejay Diagnostics Inc (NAS:BJDX) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

N/A

Address

360 Massachusetts Avenue, Suite 203, Acton, MA, USA, 01720

Website

https://www.bluejaydx.com

Bluejay Diagnostics Inc is a medical diagnostics company. It is engaged in developing, manufacturing, and marketing of clinical diagnostic products that improve the quality of medical diagnoses. The company's first product, the Symphony IL-6 test, is for the monitoring of disease progression in critical care settings. The company is a provider of rapid tests for infectious, inflammatory, and metabolic diseases by the Symphony platform.

Executives

Svetlana Dey	director, 10 percent owner	360 MASSACHUSETTS AVE, SUITE 203, ACTON MA 01720
Indranil Dey	director, 10 percent owner, officer: Chief Technology Officer	360 MASSACHUSETTS AVENUW, SUITE 203, ACTON MA 0170
Frances P Scally	officer: CFO	66 MELANIE LANE, SYOSSET NY 11791
Jason Cook	officer: Chief Technology Officer	360 MASSACHUSETTS AVE, SUITE 203, ACTON MA 01720
Kenneth R Fisher	officer: Chief Financial Officer	67 PROSPECT STREET, PEABODY MA 01960
Douglas Clark Wurth	director, 10 percent owner	4265 SAN FELIPE, SUITE 603, HOUSTON TX 77027
Gordon Winston Kinder	officer: Chief Financial Officer	360 MASSACHUSETTS AVENUE, SUITE 203, ACTON MA 01720
Gary G Gemignani	director	C/O IASO PHARMA INC., 12707 HIGH BLUFF DRIVE, SUITE 200, SAN DIEGO CA 92130
Fred S Zeidman	director	109 NORTH POST OAK LANE, SUITE 422, HOUSTON TX 77024
Donald R Chase	director	39 TIMBER RIDGE RD., WEST SPRINGFIELD MA 01089